Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome
European Journal of Haematology · 2026-07 · 117 (1) · 227-234
DOI: 10.1111/ejh.70185 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 02.04.2026. Verfasst von Louise Olsson Werne und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Skåne University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, B-Cell, Receptors, Chimeric Antigen, Biological Products. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study investigates the expansion of CAR T‐cells and its association to treatment outcome.
Methods
Patients with aggressive B‐cell lymphomas treated with anti‐CD19 CAR T‐cell therapy axicabtagene ciloleucel (axi‐cel) at Skåne and Sahlgrenska University Hospitals from 2019 to October 2024 were included. CAR T‐cells in peripheral blood were measured by flow cytometry. Association between maximum levels of CAR T‐cells and response, progression‐free survival, overall survival, cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) were investigated.
Results
Peak CAR T‐cell levels were higher among patients with complete response (CR) at Day 30 ( p = 0.013) and at 12 months ( p = 0.036). CD8 + CAR T‐cells were higher in patients with CR (median 135.7, IQR 52.8–433.9) compared to patients not obtaining CR (median 23.2, IQR 11.1–103.3) ( p = 0.003). The ratio of CD4 + :CD8 + CAR T‐cells was lower in patients obtaining CR ( p = 0.046). Patients with CAR T‐cells above 52.4 CAR T‐cells/μL showed superior progression‐free survival ( p < 0.001).
Conclusion
Our study indicates that CAR T‐cell levels after axi‐cel correlate to durable response, progression‐free survival, and that expansion of CD8 + CAR T‐cells might be of specific importance for efficacy. Potentially, CAR T‐cell levels may be used to enable early detection of patients with high risk of CAR T‐cell treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Skåne University Hospital, Lund, Sweden.
- Faculty of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
- Department of Clinical Immunology and Transfusion Medicine, Skåne University Hospital, Lund, Sweden.
- Division of Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.
- Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Hematology, Skåne University Hospital, Lund, Sweden.
ORCID-Profile: Louise Olsson Werne, Evelina Elmér
Zitieren
APA
Werne, L. O., Elmér, E., Lisak, M., Pálmason, R., Hult, A. K., Dykes, J., & Jerkeman, M. (2026). Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome. European Journal of Haematology, 117(1), 227-234. https://doi.org/10.1111/ejh.70185
Vancouver
Werne LO, Elmér E, Lisak M, Pálmason R, Hult AK, Dykes J, et al. Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome. European Journal of Haematology. 2026;117(1):227-234. doi:10.1111/ejh.70185
BibTeX
@article{Werne2026,
author = {Werne, Louise Olsson and Elmér, Evelina and Lisak, Mikael and Pálmason, Róbert and Hult, Annika K and Dykes, Josefina and Jerkeman, Mats},
title = {Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {227--234},
doi = {10.1111/ejh.70185}
}
EUVIMED